M&A Deal Summary

Karo Pharma Acquires Biophausia AB

On November 1, 2016, Karo Pharma acquired life science company Biophausia AB from Medivir for 908M SEK

Acquisition Highlights
  • This is Karo Pharma’s 2nd transaction in the Life Science sector.
  • This is Karo Pharma’s 2nd largest (disclosed) transaction.
  • This is Karo Pharma’s 3rd transaction in Sweden.

M&A Deal Summary

Date 2016-11-01
Target Biophausia AB
Sector Life Science
Buyer(s) Karo Pharma
Sellers(s) Medivir
Deal Type Divestiture
Deal Value 908M SEK

Target

Biophausia AB

Stockholm, Sweden
website
Biophausia AB is a pharmaceutical company. Biophausia provides cost-effective pharmaceuticals and focuses on three fields: generic products, niche products and original drugs.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Karo Pharma

Stockholm , Sweden

website


Category Company
Founded 1987
Sector Life Science
Employees225
Revenue 3.0B SEK (2021)
DESCRIPTION

Karo Pharma is a specialty pharmaceutical company in the Nordics. The company develops and markets products for pharmacies and directly to the healthcare sector. The product portfolio includes over-the-counter and prescription pharmaceuticals as well as medical devices. Karo Pharma was incorporated in 1987 and is based in Stockholm, Sweden.


DEAL STATS #
Overall 3 of 5
Sector (Life Science) 2 of 3
Type (Divestiture) 1 of 1
Country (Sweden) 3 of 4
Year (2016) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-02 Swereco Group AB

Stockholm, Sweden

Swereco Group AB produces a wide range of products for people with limited mobility and functional disabilities, including crutches and walking frames as well as ergonomic products for bathrooms and kitchens.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2019-06-24 Trimb Healthcare AB

Stockholm, Sweden

Trimb Healthcare AB is a pharmaceutical company focuses on sales, marketing, and development of prescription free (OTC) pharmaceuticals and consumer healthcare products. Trimb owns licenses to, markets and sells a large number of over-the-counter pharmaceuticals and consumer healthcare products. Trimb has a portfolio of leading brands focused on skin care, foot care, oral care, and intimate health categories.

Buy kr3.4B

Seller(S) 1

SELLER

Medivir

Huddinge, Sweden

website


Category Company
Founded 1987
Sector Life Science
Employees9
Revenue 4M SEK (2022)
DESCRIPTION

Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. Medivir is a competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Medivir was founded in 19887 and is based in Huddinge, Sweden.


DEAL STATS #
Overall 2 of 2
Sector (Life Science) 1 of 1
Type (Divestiture) 2 of 2
Country (Sweden) 2 of 2
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2011-06-16 Biophausia AB

Stockholm, Sweden

Biophausia AB is a pharmaceutical company. Biophausia provides cost-effective pharmaceuticals and focuses on three fields: generic products, niche products and original drugs.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-12-29 TetraLogic Pharmaceuticals - Oncology Programs

Malvern, Pennsylvania, United States

TetraLogic Pharmaceuticals Corp. - Oncology Programs includes clinical stage oncology programs MAC Mimetic and HDAC Inhibitor Assets.

Buy $12M